AFT CFO Malcolm Tubby to retire; Simon Bosley CFO Designate

19 NOVEMBER 2025 AFT CFO Malcolm Tubby to retire; Simon Bosley CFO Designate AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces its Chief Financial Officer Malcolm Tubby is to retire at the end of May 2026 after a long career with the company. It also announces Simon Bosley will assume the role of CFO designate from Monday 24 November 2025 and will progressively assume responsibilities through a structured handover. AFT Chair David Flacks said: “On behalf of the Board, I want to sincerely thank Malcolm for his outstanding contribution to AFT over many years. He has played a key role in shaping our financial strategy and supporting the company’s growth from its formation with a small presence in New Zealand, to a company that now is selling in 85 countries, is listed on both the NZX and ASX, and is now tracking towards generating $300 million in annual revenue. We are very grateful for Malcolm’s commitment to the company, his professionalism, and integrity. “We are also delighted Simon Bosley has agreed to join the company. Simon brings to AFT deep financial expertise in both public and private markets together with strong leadership skills. The Board is confident that Simon is well placed to support the next phase of AFT’s strategy and growth.” Simon joins AFT from Hirepool New Zealand, a market leader in the New Zealand equipment hire industry, serving customers across a broad range of industries. Prior to that he was CFO of NZX-listed timing and frequency control company Rakon. He has also held senior financial roles with Sony in New Zealand and Australia. He is a Chartered Accountant and holds a Bachelor of Commerce from the University of Auckland. AFT Pharmaceuticals Co-Founder and Managing Director Dr Hartley Atkinson said: “We are grateful for Malcolm’s contribution over the years to help us transition from literally the garage to a publicly listed company on the NZX and ASX, and now to grow our business around the globe. We wish Malcolm all the best for his retirement and appreciate the structured handover that will now proceed with Simon joining the company ahead of Malcolm leaving. “I am meanwhile looking forward to working with Simon. He has a strong track record which will be needed as we drive the business expansion. Together with our great team, I am confident he will help drive the all-important results delivery to extend our unbroken record of growth” Reflecting on his upcoming retirement, Malcolm Tubby said: “It has been a privilege to serve as CFO of AFT. I am proud of what we have achieved so far, and I am looking forward to watching future progress. I would like to thank the Board, Hartley, Marree and my colleagues across the business, our investors and our partners, for the opportunities and support they have provided over the years.” Simon Bosley said: “I am delighted to be joining AFT. Since its formation the company has established a remarkable record of delivering growth year-on-year and now decade-on-decade. The AFT team have demonstrated a proven ability to identify un-met health needs and to in-license or develop medicines to meet those needs both in New Zealand and further afield. With the company having established footholds in new markets, it is poised for a new phase of growth, and I am looking forward to helping the company on this journey.” Released for and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer. For more information Investors Media Dr Hartley Atkinson Richard Inder Managing Director The Project AFT Pharmaceuticals Tel: +64 21 645 643 Tel: +64 9 488 0232 About AFT Pharmaceuticals AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of medicines across OTC, prescription and hospital channels. The portfolio comprises proprietary and in-licensed products across pain management, dermatology, eyecare, allergy, gastro and other categories. AFT commercialises products directly in Australia, New Zealand, Singapore, Malaysia, Hong Kong, the US, Canada, the EU (ex Ireland) and the UK, and out-licenses to partners in more than 125 countries.